¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º ~U3S eo }  
ki#b PgT  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ LZa % x  
mqw 84u  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) (-J<Vy]  
1fRP1  
1. ICAM-1 2LC w*eT{)  
C99&L3bz^(  
2. interleukin 12(IL-12) 7f* RM  
j_V/GnEQ  
3. tumor infiltrating lymphocyte %I0}4$  
x) 5LT}p  
4. TCR/CD3 complex >jKjh!`)!e  
#D0 ~{H  
5. hematopoietin receptor family R>HY:-2  
^cn@?k((A  
6. individual idiotype(IdI) A%n?}  
NNp}|a9  
7. integrin $ 9=8@  
32^#RlSu8  
8. colony-stimulatory factor (CSF) - wWRm  
Eu4 &-i  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© C`EY5"N r  
'kEG.Oq7  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? s~Gw  
*(Ro;?O,pi  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ s`1^*Dl%+  
AK;^9b-}q:  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠF|*tNJU>  
Gnv!]c&S>l  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ y@aKNWy}$  
+f$Z-U1H/  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) @ t|3gF$X  
dQK`sLChv  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ 5{>>,pP&  
C=yD3mVz  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) 67?n-NP  
8$m1eQ`{  
3. immunoglobulin superfamily (IgSF) Bj8<@~bX:L  
Q0WY$w1 <  
4. selectin ~b#OFnyG  
ftaBilkjp  
5. anti-idiotypic antibody (¦ÁId) 1OP" 5f  
UO1$UF! QC  
6. major histocompatibility complex(MHC) -$9 ~xX  
1J&#&\,f&  
7. immunotolerance *l {4lu  
1@@y]s_.a  
8. biological reponse modifier(BRM) Rf?%Tv0\  
0Nt%YP  
9. immune reponse gene (Ir gene) nd;O(s;  
F:_FjxU  
10. reshaped antibody (or reconstituted antibody) CC>($k"  
i(P>Y2s  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 80HEAv,O  
d=F)y~&'  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ $YP QC  
c8q G\\t[  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? %]!?{U\*k  
0f{IE@-b  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ soDfi-2o3  
8TI#7  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? 6# R;HbkO  
PYaOH_X.  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ t:disL& !E  
TD%WJ9K\  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? *%nX#mwz  
4 #G3ew  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ q4 $sc_0i  
u$\Tg3du2  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ y^ 3,X_0  
iKY-;YK  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? ,I=O"z>9  
Z"+(LO!  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ IK85D>00T  
m[{nm95QZ  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: JW2W>6Dgv[  
WI%zr2T  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: cz$c)It  
{XyG1  
ÃâÒßѧ ud 5x$`  
o K%K+h  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© {3jm%ex  
N <ja6Ac  
1. CD8 H)-L%l|9  
;H`=):U  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) l@ (t^68OD  
i_'|:Uy*F  
3. immunoglobulin fold(Ig fold) G;87in ,}  
-(`K7T>D.  
4. cadherin (Ca-dependent cell adhesion moleculers) MA l{ 66  
mOABZ#+F k  
5. idiotype-anti-idiotypic antibody immune network theory \;4L~_2$q  
Q3'(f9 x  
6. HLA class II antigen +F#=`+V  
7/$nA< qM  
7. complementarity-determining region (CDR) +y tT)S  
 WMt&8W5  
8. perforin(or pore-forming protein ,PFP) eA;j/&qH  
:..E:HdYO  
9. high affinity IL-2 receptor 9u-M! $  
'US8"83  
10. artificial active immunization BZnp #}f  
b7F3]W<`&  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 7zz(#  
fJ|Bu("N  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠLrm tPnL  
8 RzF].)  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 'Kt4O9=p  
$A5B{2  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ @eAGN|C5  
=B ,_d0Id  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ 8_sU8q*s  
Z IGbwL  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ [xp~@5r'  
@h z0:ezg:  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? KqG$zC^N  
_Oaso >  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ /(WX!EEsB  
gzJ{Gau{)  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ " N`V*0h  
cE_Xo.:Y,  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ 2C 8L\  
<whPM  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ Hi4@ !]  
p1`'1`.3  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© r)Mx.`d!  
'piF_5(@  
1. immunoglobulin gene rearrangement )4o=t.O\K  
6lH>600]u  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) dA MilTo  
\Vhp B   
3. flow cytometry(FCM) #dn%KMo2r  
BzG!Rg|J  
4. carrier effect 3 v,ae7$U&  
SUFaHHk@/b  
5. positive selection of T lymphocytes in thymus *MyS7<  
4 *2>R8SX~  
6. mouse TH1(Th1) and TH2(Th2) subsets /\Y%DpG$  
Uc%`? +Q  
7. perforin (pore-forming protein ,PFP) PTV`=vtj  
c K}  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) [ QL<&:s&  
d-S'y-V?d  
9. SH-2(src-homology region 2)  sCf (h  
@snLE?g j  
10. Ab2¦Â (internal image) f`";Q/rG  
_/w-gL{  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© v(nQd6;T  
kviSQM2  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? {,mRMDEy  
Oj|p`Dzh  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? TXOW/{B  
I z=w2\r  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠO?J:+L(  
50hh0! 1  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ #3[b|cL  
\ rWgA  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ/F9lW}pd  
D\&y(=fzf  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) X|B;>q  
Gbm_xEPC  
ÃâÒßѧרҵ£º pP oC61F  
'9Odw@tp  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ ,%G2>PBt  
3kQ8*S  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? cZT.vA#  
|VEAzY|[#  
´«È¾²¡Ñ§×¨Òµ£º *pUV-^uo  
 FAl6  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ ;<R_j%*  
_%%"Y}  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ Ui;s.f  
?bDae%>.d,  
Ïû»¯×¨Òµ£º n k3lC/f  
%Z0S"B 3  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ = }lA|S  
d+ko"F|  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? <]qd9mj5  
Dx)XC?'xO  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ yyDBW`V((  
WN1-J(x6  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© o@;_(knb  
k (+u"T  
1. Fas(CD95)/FasL #vwXxr  
i_ Td I  
2. common chain of cytokine receptor YcZ4y@6"  
N)Kr4GC  
3 . TCR/CD3 complex +N_%|!F-c  
qEz'l'%(  
4. negaive selection of thymocytes A@'W $p?5r  
6LQO>k  
5. artificial active immune XLxr~Yo  
*4y r7~S5  
6. anti-idiotypic Xy&#}S}9  
5 Vqvb|  
7. IgSF *X=-^\G  
J)NpG9iN  
8. Integrin tn1aH +  
h]P$L>  
9. chemokine c Zr4  
r%n[PK^(  
10. B7/CD28 .5xg;Qg\Y  
P s ;:g0  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© ic#drpl,  
:g";p. ~=  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ rOT8!"  
6B{Awm@v}X  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ )' #(1 ,1k  
dz 2d`=`3  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ lR!$+atW  
wBET.l'd  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ p2K9R4  
1-#tx*>AY  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ GZo4uwG@a  
W]OT=6u8o  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ +|;IIwo  
7F4]EA ^  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© s-B\8&^C  
n6f|,D!?  
1. B7/CD28 f/ZE_MN2  
3 [rB:cE/  
2. Th1 subset jo~Pr  
L/I-(08!Y:  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© _f`m/l  
V|)>  
4. antibody affinity maturation 7-DC"`Y8e  
@!$NUY8,A#  
5. AP-1 L;"<8\vWB  
u#\3T>o%@  
6. single chain variable fragment£¨ScFv£© d\ v _!7  
8~i@7~ J  
7. NK cell receptor <_![~n$H  
Li2)~4p><  
8. Zinkernagel-Doherty phenomenon _MU'he^W  
S,H{\c  
9. Ig fold P(`IY +  
.<.qRq-  
10. CD40/CD40L "hfwj`U  
0`W~2ai  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© B:4u 2/!5  
f As:[  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ +K?h]v]%  
K  +~  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ 6]Jv3Re'(I  
Y%faf.$/9  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ GYYro&aq{  
g=pDC+  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ x\jHk}Buj  
H)S3/%.|  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ Pc3u`QL?  
=4zsAa  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ 9K49<u0O  
'/j`j>'!^  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ E|>I/!{u7`  
"\9@gfsp)  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© v zn/waw  
8{ep`$(K@  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© DirWe  
0h7\zoZ5  
1.Co-stimulators (or co-stimulating molecules) #U1soZ7  
+o/q@&v;Ax  
2.NK-kB DxYu   
?eu=0|d  
3.Immunoglobulin superfamily r[gV`khka  
{[$p}#7Y  
4.antigen-presenting cell (APC) EU+sTe>  
VHJr+BQ1K/  
5.death domain A$5T3j'  
lj[Bd >  
6.CCR and CXCR ?XHJCp;f  
 oCduY2  
7.Lectin (or mitogen) t*DM^. @  
#&@&BlIe  
8.Clusters of differentiation, CD) iw#luHcJ  
|BXq8Erh  
9.B7 family 3Mdg&~85  
#>233<  
10.Cytotoxic T lymphocyte, CTL) 9oaq%Sf   
'n=FBu ^  
11.IL-15 and IL-15 receptor (IL-15R) `xtN+y F  
J)R2O4OEd  
12.MHC restriction 3{:d$- y  
.$q]<MK8  
13.Affinity-chromatography {L8SD U{P  
u^{Q|o:=x  
14.Cyctosprin A, CsA \O^= Z{3y  
t rHj7Nw  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) K46mE   
k_!z=6?[:  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© 7$^V_{ej  
 fBQZ=zh  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 Tp9LBF  
@ #V31im"N  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ 4b a1c  
'2%hc\P6P  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ KYlWV<sR  
~>C!l k  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© /1O6;'8He  
b?r0n]  
ÃâÒßѧרҵ£º z9VQsC'K  
Ron^PvvY&  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ >f_D|;EV  
!'+t)h9^  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ X-t4irZ)  
Qi[T!1  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ |=7%Edkd  
EkJo.'0@  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) xNjA>S\]W5  
~r!jVK>^  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) G"J6X e  
T nPC\.x  
1. ADCC(antibody dependent cell-mediated cytotoxicity) "b2Mk-qP  
@UvjJ  
2. »·æß¾úËØ(cyclosporin) m V^dIm  
&npf %Eub  
3. KIR(killer cell inhibitory receptor) ph69u #Og  
OxqP:kM  
4. HLDA(human leucocyte differentiation antigen) W[YcYa_tQ  
I</Nmgf  
5. Interleukin 18(IL-18) 9N9|hy  
ib& |271gG  
6. ÕûºÏËØ(integrin) 4N*^%  
'X` \vTxB  
7. Fas/FasL uE/q ra A  
6#dx%TC  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) i3f/ {D/  
t 6~|T_]  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) :<nL9y jt  
d[ {=/~0  
10. Th1/Th2 Ph-3,cC  
8whjPn0  
11. »ùÒòÒßÃç(DNAÒßÃç) {_Wtk@  
c?wFEADn  
12. chemokines and chemokine receptor ujDAs%6MZ  
BhNwC[G?m  
13. ÃâÒßÄÍÊÜ n) `4*d$`  
{K:/(\  
14. ¹²´Ì¼¤·Ö×Ó x~KS;hA  
b/<4\f  
15. ËÀÍö½á¹¹Óò(death domain) 8f#YUK sW=  
1=#`&f5f&  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) =(v/pLLK?  
'?Hy"5gUA  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? LgB}!OLQ  
>Utn[']~  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠP`RM"'Om  
d6~wJMFl  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î |RHX2sso  
4|x5-m+T  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ hLO nX<%a  
]}C#"Xt  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå [gD02a: u  
zoO>N'b3)  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ 2{ }5WH  
Pq;1EI  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) LvE|K&R|  
4dl?US[-  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ 7*u0)Hog  
'g( R4deCX  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ m_U__CZ}Tt  
Hk$|.TjzI  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
freekaobo¹Ù·½Î¢ÐŶ©ÔĺŠÕýÈ·´ð°¸:¿¼²©
°´"Ctrl+Enter"Ö±½ÓÌá½»